ArticleResearch square2026
Divergent hepatitis B neutralizing antibody trajectories after spontaneous control in people with and without HIV.
Che-Min Lo, Eric C Seaberg, Mark Anderson, Maraake Taddese, Jessica L Mimms, Ernesto T Marques, Mallory D Witt, Steven M Wolinsky, Gavin Cloherty, Justin R Bailey and 1 more
Abstract readPreprint
In one paragraphArticle in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Che-Min LoDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Eric C SeabergDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Mark AndersonDiscovery Research, Abbott Laboratories, Abbott Park, Illinois, USA.
Maraake TaddeseDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jessica L MimmsDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ernesto T MarquesDepartment of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-3826-9358 Mallory D WittLundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Steven M WolinskyDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0002-9625-6697 Gavin ClohertyDiscovery Research, Abbott Laboratories, Abbott Park, Illinois, USA.
Justin R BaileyDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Chloe L ThioDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-8851-8319 Funding
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1MVirology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1MEngaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0MVirology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MQAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7MMaternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8MUNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3MSex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8MUniversity of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Savita Pahwa · 2007 to 2026
$33.8MClinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center - Admin Supplement: Vision and dual sensory loss in HIV-infected older adultsU01HL146201 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Joseph B. Margolick · 2019 to 2026
$33.7MUniversity of Pittsburgh MWCCS Clinical Research SiteU01HL146208 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Bernard Jonas C Macatangay, CHARLES R RINALDO · 2019 to 2026
$32.2MNCATS NIH HHS KL2 TR001432NCATS NIH HHS TL1 TR001431NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR001409NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1 TR003098NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146201NHLBI NIH HHS U01 HL146208NHLBI NIH HHS U01 HL146240NHLBI NIH HHS U01 HL146333NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI073961NIAID NIH HHS P30 AI124414NIEHS NIH HHS P30 ES010126NIMH NIH HHS P30 MH116867
6 · The paper itselfAbstract
People with HIV (PWH) have reduced spontaneous control (SC) of acute hepatitis B virus (HBV) infection and increased risk of HBV reactivation, but whether protective antibodies against hepatitis B surface antigen (anti-HBs) remain functional after SC is unclear. We analyzed longitudinal antibody responses of 136 men in the MACS/WIHS Combined Cohort Study with incident HBV followed by SC (99 people without HIV [PWoH], 37 PWH) at the first visit consistent with SC and approximately 6 and 30 months later. Anti-HBs titers increased over 2.5 years after SC in PWoH but not PWH. Similarly, HBV neutralization was higher after SC in PWoH and remained stable, while trending downward in PWH. In contrast, antibodies against core antigen declined similarly in both groups. Unexpectedly, hepatitis B surface antigen-anti-HBs immune complexes (HBsAg ICs) were present in the majority of samples and remained stable over time. These findings support persistent HBsAg production after SC, which leads to increasing functional anti-HBs control in PWoH that is impaired by HIV potentially explaining effects of HIV on recovery and reactivation risk.
Identifiers
PMID42620045
PMCPMC13484408
What OpenQuestion holds
Textmetadata
Read underepoch 390